Upharmacia April 2017
PHARMA MARKET NEWS
Russian Drugs and Medical Devices could be Prohibited in Ukraine
Acting Minister of Healthcare of Ukraine Ulana Suprun declared the intention to initiate the prohibition of Russian drugs and medical devices in Ukraine . Mrs . Suprun stated that currently the Ministry does not approve registration or reregistration of drugs , which are produced or even packed and imported from Russia , as “ there is a lot of questions regarding the quality of Russian medicines and medical devices ”. “ The Ministry is developing amendments to the Order of the President of Ukraine to include Russian drugs and medical devices in the sanction list ,” Mrs . Suprun said . “ This is a political decision of the Ministry . Ukr aine is at war with Russia . It is wrong that we add to their economy additional funds from our state budget , buying drugs .”
Ukraine is the biggest importer of Russian drugs . In 2016 , Russia supplied drugs in Ukraine for RUB 2.1bn . According to calculations of RNC Pharma , Russian companies may lose RUB 1.7bn in 2017 , if Ukraine impose sanctions on Russian drugs . Almost all Russian drugs and medical devices have substitutions on Ukrainian market , so the prohibition would not affect the patients drastically , the acting Minister considers . Russian imports in Ukraine were failing over the last years , while imports to the occupied territories of Donetsk and Lugansk regions are increasing .
Pharmstandard
Sold 50 %
Share in Boilek
Russian pharmaceutical company Pharmstandard decreased the share of Ukrainian producer of vaccines and immunobiological preparations Biolek from 96.93 % to 46.93 %. The buyer of shares is undisclosed .
Pharmstandard acquired 55 % share of Biolek in 2011 for USD 13.1 mio . In 2013 , the share of Russian company increased to 97 %. Pharmstandard is one of the biggest pharmaceutical companies in Russia with about 5.5 ths employees .
Biolek is among TOP-20 Ukrainian producers of vaccines , infusion and injection drugs . In 2015 , the company ’ s income amounted USD 5.9 mio .
Farmak Launched Gep-Art
Ukrainian pharmaceutical company Farmak launched the drug for the treatment of liver Gep-Art ( ademetionine ). The drug fills the shortage of endogenous ademetionine and stimulates its production in the body . Gep-Art is indicated for the treatment of intrahepatic cholestasis in adults and pregnant . The drug is sold only by prescription .
Farmak retained first position on Ukrainian retail drug market in 1Q2017 . Drugs for alimentary tract and metabolism form about 21 % of the company ’ s portfolio .
Acino Pharma Start signed Distribution Agreement with French Company
In Feb , Ukrainian company Acino Pharma Start signed agreement with French company Laboratoires Gilbert SAS on the right of commercial sale of some OTC drugs in Ukraine . From Apr 2017 to 2024 , Pharma Start ( part if Swizz ACINO Group ) will be representing 3 trademarks of Laboratoires Gilbert . These trademarks are : Marimer ®, A-Cerumen Neo ® and Liniderm . First two trademarks were earlier represented in Ukraine by Takeda Ukraine .
Marimer ® ( seawater ) is the mean for daily hygiene of the nasal cavity . A-Cerumen Neo ® possesses 60 % of the segment of hygiene products for external ear canal . Liniderm ( almond oil / calcium hydroxide ) is used for to care for a baby ’ s
6 www . upharma-c . com